Gilead Sciences, Inc. (GILD)
Pre-market:
| Previous close | 63.50 |
| Open | 63.48 |
| Bid | 64.06 x 400 |
| Ask | 64.09 x 500 |
| Day's range | 63.07 - 64.33 |
| 52-week range | 63.07 - 87.87 |
| Volume | |
| Avg. volume | 6,897,066 |
| Market cap | 79.834B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 178.00 |
| EPS (TTM) | 0.36 |
| Earnings date | 08 Aug 2024 |
| Forward dividend & yield | 3.08 (4.81%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | 81.21 |
Business WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
FOSTER CITY, Calif., May 31, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previou
Business WireGilead Provides Update on Phase 3 TROPiCS-04 Study
FOSTER CITY, Calif., May 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.
Business WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
